Sign up
Tech Capital

Amphion Innovations trims its stake in Motif Bio

Life sciences and technology incubator Amphion Innovations recently rolled over £6.56mln of promissory notes due in December 2018 for a year.
US dollars
One-third of the proceeds from the sale will be retained for working capital

Amphion Innovations PLC (LON:AMP) has reduced its stake in partner company Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) to 7.88%.

It sold 1.83mln shares in Motif, generating US$144,000, two-thirds of which will go to effect partial repayment of the loan facility it took out in mid-2014.

READ: Motif Bio to manage cash aggressively after making loan repayment

Prior to the sale, Amphion’s stake in Motif Bio, which is developing iclaprim, a next-generation antibiotic, was 8.51%.


 

John-H.jpg
Why Invest In Amphion Innovations PLC? Read More Here

Register here to be notified of future AMP Company articles
View full AMP profile View Profile
View All

Related Articles

© tech Capital 2019

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.